Rationale Gamma-hydroxybutyrate acid (GHB), a GABA B receptor agonist approved for treatment of narcolepsy, impairs driving ability, but little is known about doses and plasma concentrations associated with impairment and time course of recovery. Objective To assess effects of oral GHB (Xyrem®) upon driving as measured by a driving simulator, and to determine plasma concentrations associated with impairment and the time course of recovery. Methods Randomized, double-blind, two-arm crossover study, during which 16 participants received GHB 50 mg/kg orally or placebo. GHB blood samples were collected prior to and at 1, 3, and 6 h post dosing. Driving simulator sessions occurred immediately after blood sampling. Results Plasma GHB was not detectable at baseline or 6 h post dosing. Median GHB concentrations at 1 and 3 h were 83.1 mg/L (range 54-110) and 24.4 mg/L (range 7.2-49.7), respectively. Compared to placebo, at 1 h post GHB dosing, significant differences were seen for the life-threatening outcome collisions (p < 0.001) and off-road accidents (p = 0.018). Although driving was not faster, there was significantly more weaving and erratic driving with GHB as measured by speed deviation (p = 0.002) and lane position deviation (p = 0.004). No significant impairment regarding driving outcomes was found in the GHB group at 3 and 6 h post dose. Conclusion GHB in doses used to treat narcolepsy resulted in severe driving impairment at 1 h post dosing. After 3 to 6 h, there was full recovery indicating that safe driving is expected the next morning after bedtime therapeutic GHB use in the absence of other substances.
Introduction
Gamma-hydroxybutyrate (GHB) is a therapeutic drug approved in 2002 by the U.S. Food and Drug Administration in the form of sodium oxybate (Xyrem®) as a Schedule III drug to treat narcolepsy and cataplexy (Product Information: Xyrem®; Fuller et al. 2004; Borgen et al. 2002) . The recommended starting dose is 4.5 g per day divided into two doses (2.25 g each), one taken at bedtime and the other 2.5 to 4 h later. The dose for narcolepsy is then titrated up to therapeutic effect over days to a maximum dose of 9 g per day, divided into two 4.5 g doses (Product Information Xyrem®). In addition to narcolepsy and cataplexy, GHB is used in Europe for the treatment of alcohol withdrawal and dependence (Drasbek et al. 2006) . According to the website of Xyrem® (www.xyrem.com), as of 2015, almost 60,000 people have been prescribed the drug. Furthermore, GHB had been marketed as a dietary weight loss supplement in Evangelia Liakoni and Delia A. Dempsey contributed equally to this work.
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health food stores and later promoted on the internet as an agent for bodybuilding (Anderson et al. 2006; Gonzalez and Nutt 2005) . Due to its euphoria-producing effects, GHB is also used as a recreational substance (Miró et al. 2017; Liakoni et al. 2016; Busardò and Jones 2015) and has been implicated in drug-facilitated sexual assault (ElSohly and Salamone 1999; Gonzalez and Nutt 2005) . Although the exact prevalence of GHB abuse is not known and available data probably underestimate the true extent, reported estimates for lifetime use are between 0.5 and 1.4% among students, with higher estimates (3-19%) in specific subpopulations (e.g., men who have sex with men), settings (e.g., club and dance venues), and geographical areas (EMCDDA 2008) . Typical recreational doses are usually 2.5 g (~35 mg/kg for a 70-kg person) or more but vary widely (chronic users may use much higher doses several times per day) (Couper and Marinetti 2002) .
The primary effect of GHB is depression of the central nervous system (Dempsey et al. 2007; Thai et al. 2006) . Although it also exists as an endogenous chemical, the profound action that GHB has in high doses on the CNS is attributed primarily to a direct agonist effect on the GABA B receptor (Drasbek et al. 2006; Snead III and Gibson 2005) . GHB has been associated with driving impairment (Centola et al. 2018) , with the first case reported in 1994 (Stephens and Baselt 1994) . Since then, other cases have been described in both the USA (National Drug Intelligence Center 2002) and Europe (Bosman and Lusthof 2003; Al-Samarraie et al. 2010) , with clinical observations including unsafe driving behavior, extreme sleepiness, and reduced consciousness. Although those reports are mostly associated with GHB abuse, some of the estimated recreational doses are in a similar range to that used in therapeutic setting and Bsleep-driving^has also been reported in patients taking Xyrem® for narcolepsy (Wallace et al. 2011) .
While many reports indicate that GHB impairs driving, little is known of the dose-response and duration of impairment. The aim of the present study was to determine the effect of therapeutic doses of GHB upon the ability to drive as measured by a driving simulator previously validated in alcohol driving impairment studies (Moskowitz et al. 2000) . We also examined the temporal aspects of the GHB effect upon driving, assessing performance for up to 6 h after taking GHB, and the relationship between blood concentrations of GHB and impaired driving.
Methods
Overall design This was a sex-balanced, randomized, doubleblind, two-arm crossover study of GHB and placebo conducted on two different days. On each study day, the participants performed a baseline session on the driving simulator and were then dosed with either placebo or GHB, in counterbalanced order. Driving simulator sessions were performed at 1, 3, and 6 h post dosing. On both study days, blood was collected for GHB analysis at baseline and immediately prior to each driving session. GHB analyses were then performed as described subsequently. This study was performed with informed consent and with the approval of the Committee on Human Research of the University of California, San Francisco.
Participants Sixteen healthy adults were enrolled. Inclusion criteria were that participants must be either naïve to or at most an occasional user of GHB (i.e., less than three times per year), possess a valid driver's license, not be taking any prescription medications other than contraceptives, and be between the ages of 21-45. Exclusion criteria included any significant medical conditions, pregnancy, obesity (body mass index (BMI) ≥ 30), substance abuse or prescription drug use that could not be stopped for 2 weeks prior to the study, and alcohol consumption of more than 5 drinks/week.
Recruitment Participants were recruited through newspapers and online advertisements and flyers posted in San Francisco Bay Area cafes, colleges, etc., and instructed to call a phone screening line. Potential participants were initially screened over the phone and then in person. Informed consent was obtained and eligibility was determined through medical history, physical exam, blood testing, and urine toxicology.
Driving simulator The driving simulator used was developed by Systems Technology, Inc. of California (Hawthorne, CA) and has been used extensively in previous studies to investigate the effect of alcohol upon driving (Moskowitz et al. 2000) . This computer-based system used three video monitors to present an approximately 110°viewing angle of the road ahead as well as the periphery. The image presented on all three monitors responded to input from a steering wheel, accelerator, and brake, with appropriate visual and sound feedback. While the primary task was to obey the usual rules of the road, participants were also asked to simultaneously detect visual signals in their peripheral vision. The divided attention task involved monitoring the peripheral video screens for brief signals instructing them to honk the horn or signal for a left or right turn. During the training session, participants were instructed that turn signals were required for the divided attention task, but not for the driving task of the simulator, and a study session was scheduled only after demonstrating proficiency in the test. In total, 72 signals occurred at random intervals during the drive, at a visual angle of 55°from center.
To simulate normal driving conditions, the session was broken into three scenarios including urban, suburban, and rural driving situations, all with 12-ft lane widths. The rural segment was a straight one-lane road with shallow curves (radii ranged from 5000 to 8333 ft). Random occasional wind gusts, based on sine waves, increased steering difficulty. Because in this segment the participants did not have to interact with other traffic on a continuous basis, speed and lane positions were measured without confounds. The suburban segment consisted of a three-lane expressway with posted speed limits of 45 to 55 mph. Frequent lane changes were necessary to pass other vehicles, or to avoid cross traffic, entering traffic, and stalled cars. The urban segment was a twolane roadway through a city with buildings shown in the background and posted speed limits of 25 to 45 mph with 11 signal-controlled intersections. Pedestrians entered and crossed the walkways at the signals. Participants were instructed to drive as close as possible to the posted speed limit. In all scenarios, a crack appeared on the windshield and a crashing sound was heard in case of a collision, accident, or pedestrian hit. Following an accident, lane position was reset to a default position. The total drive distance for all three segments was approximately 12 miles and each driving session typically lasted 18 to 20 min. Table 1 gives the outcome measures used by this driving simulator.
Participants extensively practiced on the driving simulator prior to the inpatient study days to familiarize themselves with the driving interface. Practice included two 4-h teaching sessions and an 8-h mock study day, at which the participants performed simulator sessions at 7, 8, and 9 am, noon, and 3 pm. Upon reaching an acceptable level of proficiency, participants were then scheduled for the two 24-h inpatient admissions. Thus, the entire study included the screening visit (2 h), two practice visits (4 h each), one mock study day (8 h), and the two inpatient study days (approximately 24 h each). Participants performed one final early morning practice session prior to the pre-dose baseline session.
Study procedures This was an inpatient study conducted at the General Clinical Research Center at Zuckerberg San Francisco General Hospital and Trauma Center. Participants spent the night there before each study day. Prior to admission, participants were asked to refrain from drinking alcoholic beverages for 3 days and to fast and abstain from caffeine and tobacco products overnight. Participants received a light breakfast between 6:30 and 7 am and then performed the final practice driving session. Between 7 and 8 am, a peripheral venous catheter for blood sampling was placed. A baseline driving session was performed at 8 am, dosing with GHB or placebo at 9 am, and post dosing driving sessions at 10 am, noon, and 3 pm. Blood samples for GHB analysis were collected prior to dosing (baseline) and at 1, 3, and 6 h post dosing to correlate with each of the driving sessions. Blood samples were collected through a peripheral intravenous catheter placed in the right forearm, on a The standard deviation of the response times site believed to least interfere with using the driving simulator. Prior to each driving session, participants completed a brief self-assessment questionnaire regarding their perception of their ability to drive. The self-assessment questionnaire had a scale of 1 to 5, 1 being no impairment and 5 being maximally impaired. Participants completed the three driving sessions at 1, 3, and 6 h post dosing and were discharged at 5 pm on each study day (i.e., 8 h after dosing), unless still symptomatic, in which case they could stay overnight. The two arms of the cross-over study (i.e., GHB and placebo) were separated by at least one night.
GHB and placebo dosing Xyrem® (Orphan Medical Co., Minnetonka, MN) contains 500 mg/mL of sodium oxybate, corresponding to 413 mg/mL of GHB. Participants were dosed at 50 mg GHB per kilogram of body weight. To determine the study dose, the screening weight was used, unless the study day weight was significantly different (i.e., > 10% difference). The dose was calculated based on GHB and not sodium oxybate. The dose calculation was adjusted during the study due to four male participants developing nausea and vomiting (both common adverse effects of GHB (Product Information Xyrem®; Miró et al. 2017) ) rendering them incapable of completing the 1-h driving session after taking GHB at 50 mg/kg dose. Thus, four additional males were enrolled to replace those who became ill, and the maximum GHB dose for these participants was lowered to 3300 mg (50 mg/kg dose for a 66-kg participant), regardless of weight. Using that maximum dose, the lowest GHB dose received by a participant was 45 mg/kg. Only the 16 participants who completed all aspects of the study are included in the results. The placebo dose was the same volume of liquid as the GHB dose, and the taste and consistency of the placebo and GHB were similar. The GHB or placebo was mixed with the participants' choice of either cranberry or orange juice. Grapefruit juice and products were not allowed in order to avoid any interactions through the inhibitory effects on metabolizing enzymes.
Determination of GHB in plasma The GHB plasma analysis was performed by a gas chromatography-mass spectrometry method similar to the method used in previous studies (Thai et al. 2006 (Thai et al. , 2007 . The detailed description of the method can be found as Online Resource. Briefly, the plasma samples were extracted by protein precipitation with isopropanol, dried, and derivatized with tert-butyldimethylsiyl trifluromethane sulfonate (TBDMS triflate) and trimethylamine in heptane at 65°C with sonication to facilitate derivative formation.
Statistics In a within-subject analysis, not normally distributed GHB results were compared with corresponding placebo results using the Wilcoxon signed rank test. The effect size was calculated by dividing the Z value by the square root of the total number of observations; an r value of 0.1 is considered small, 0.3 medium, and 0.5 large effect size (Fritz et al. 2012) . For comparisons of independent groups, the Kruskal-Wallis test was used. Differences in self-assessment scales were tested using a two-tailed paired sample t test. A p value < 0.05 was considered statistically significant. Correlations between GHB plasma concentrations and driving outcomes were investigated using the Spearman's non-parametric correlation test. Analyses were conducted using SPSS statistical software (IBM SPSS Statistics 23.0).
Results
Demographics Sixteen participants (eight females) were enrolled. Eight participants performed the two sessions with one night elapsed between them while eight participants completed the study with at least 1 day between the sessions (range 1-6). The mean participants' age was 27 years (range 22-42). Two out of the 16 participants reported use of GHB in the past. The mean weight was 69.1 kg (range 57.9-85.3), 66.6 kg (range 59.8-85.3) for the female and 71.7 kg (range 57.9-83.5) for male participants.
Driving questionnaire and simulator results One hour after GHB ingestion, all participants assessed themselves as less able to drive an automobile compared to after the placebo (p < 0.001). The self-assessment raw scores at 1 h post GHB dosing ranged from 2 to 5 (median 4), while post placebo dosing the same raw scores ranged from 1 to 2 (median 1). At 3 h post GHB dosing, there was still a significant difference (p = 0.001), with nearly a third of self-assessments scored at 3 or higher in the GHB arm. Figure 1 displays the mean selfassessment scores for all time points in both conditions. Table 2 presents the baseline and 1, 3, and 6 h post dose driving data in the two groups. Fig. 1 Self-assessed ability to drive (1 = able to safely drive a car, 5 = not able to drive a car; the asterisk indicates significant difference (p < 0.05) compared to placebo) Table 2 Baseline and 1, 3, and 6 h post dose driving simulator results (median (range, coefficient of variation)) Objective assessment with the driving simulator found no significant differences between the two groups at baseline, but significant differences were found at the 1-h post dosing driving session. Two of the three life-threatening adverse driving outcomes, collisions (Z = − 3.526, p < 0.001, r = − 0.62; all 16 participants had more collisions 1 h after GHB compared to placebo) and off-road accidents (Z = − 2.375, p < 0.018, r = − 0.42; seven participants had more off-road accidents 1 h after GHB compared to placebo, no participants with more off-road accidents after placebo), were significantly more likely 1 h after GHB dosing, while hitting a pedestrian did not show a significant difference (Table 2) . Other significant findings included greater mean speed deviation (Z = − 3.051, p = 0.002, r = − 0.54, greater deviation seen in 13 out of the 16 participants), and lane position deviation (Z = − 2.896, p = 0.004, r = − 0.51, greater deviation seen in 13 out of the 16 participants) after GHB. Analysis of the results of the driving simulation testing at 3 h showed no significant differences between treatment arms (Table 2) , except for the self-assessed ability to drive a car (Fig. 1) . At 6 h post dosing, there was no significant impairment in the GHB group, neither in the results of the driving simulation nor in the self-assessment of the ability to drive (Fig. 1) , but a greater mean speed deviation was seen in the placebo arm (Z = − 2.279, p = 0.017, r = − 0.42).
When comparing the 1 h significant results to the other time points, significant differences were found in the GHB arm: no. GHB dosing, blood concentrations, and correlations The mean GHB dose for all participants was 3333 mg (SD 400, range 2892-4265). The mean dose for the eight female participants was not significantly different from the mean dose for the eight male participants (3330 (SD 472.3) and 3336 (SD 346.8), respectively). No GHB was detected at baseline or at 6 h at the 5 mg/L limit of quantitation. The plasma concentrations of GHB at 1 and 3 h are shown in Table 3 .
At the 1-h time point, the GHB concentrations were not significantly different in women compared to men (p = 0.208). The correlations between 1-h GHB plasma concentrations and 1-h individual driving outcome measures were examined. Significant correlations were found between GHB plasma concentrations and mean lane position deviations (r = 0.532, p < 0.05), as well as mean speed deviations (r = 0.588, p < 0.05). Correlations between other driving scores and GHB plasma concentrations were not significant.
Discussion
To our knowledge, this is the first controlled clinical study of the effect of GHB on motor vehicle driving performance. We found that doses of GHB that are used in treating narcolepsy in non-regular GHB users can severely affect driving performance. A substantial impairment was found 1 h after GHB dosing, with significantly more life-threatening adverse driving outcomes (i.e., collisions and off-road accidents) and indicators of erratic driving (i.e., greater mean speed and lane position deviations). The third life-threatening outcome, hitting a pedestrian, and other outcomes of minor severity (e.g., number of speeding tickets, stops at traffic lights) did not show a significant difference, but they may have been averted by driving off-road (off-road accidents) or by collision, or in some cases not reaching significance due to large variability. We also demonstrated the time course of recovery through both subjective and objective measures. At 3 h, many still rated themselves less than fully able to drive (a finding not supported by the driving simulation), but there was full recovery both objectively and subjectively by 6 h post dosing.
While driving simulators do not perfectly reflect real-life driving, they are an accepted method to assess the effect of acute and residual effects of therapeutic drugs, sleep deprivation, and alcohol, illicit and/or recreational drug use upon driving performance (Akinwuntan et al. 2005; Arnedt et al. 2005; Lenne et al. 2003; Moskowitz et al. 2000; Partinen et al. 2003; Turkington et al. 2001; Weiler et al. 2000) . Driving simulator studies can be used to develop recommendations and policies regarding drug use and safe driving. Studies involving benzodiazepine-related hypnotics have had mixed results and their nighttime use may impair daytime driving (Partinen et al. 2003; Staner et al. 2005) , while other studies have concluded that no restriction should be placed on the driving licenses of persons using methadone, levo-alpha- 3-h plasma GHB (mg/L) 24.4 (7.2-49.7) 24.4 (7.2-49.7) 25 (9.7-43.6) acetyl-methodol (LAAM), or buprenorphine therapeutically for the treatment of heroin addiction (Lenne 2003) . Based on our findings, it is unlikely that bedtime/nighttime GHB correct dosing will have clinically significant effects upon daytime driving. This is in accordance with the rapid clearance of GHB as demonstrated by this and other studies (Borgen et al. 2004; Brenneisen et al. 2004; Palatini et al. 1993; Scharf et al. 1998; Thai et al. 2006) . Currently, the product information of Xyrem® (Product Information Xyrem®) includes a warning that patients should not engage in activities such as operating a motor vehicle for at least 6 h after taking the second nightly dose. Our study demonstrated that by 6 h, GHB concentrations were below 0.5 mg/L and the driving simulator scores had returned to baseline. Thus, therapeutic nighttime users of GHB should have sufficient time to recover from the GHB prior to driving in the morning.
However, driving within a few hours of GHB use appears to be hazardous. Compared to other driving simulation studies (Moskowitz et al. 2000) , the level of impairment measured in our participants by GHB at 1 h was similar to that seen in drivers with breath alcohol concentrations in the range of 0.08 to 0.1%. Furthermore, the use of combinations of GHB and other substances is not uncommon (Dresen et al. 2007) and may lead to driving impairment at lower GHB doses. In previous studies (Dempsey et al. 2007; Thai et al. 2006) , participants who ingested both ethanol and GHB were extremely sedated and had mild respiratory depression, even when the dose of GHB was lowered to 25 mg/kg. Also when ethanol and GHB are combined, ethanol may inhibit the clearance of GHB (Dempsey et al. 2007; Thai et al. 2006) .
The effects of GHB on psychomotor function, and presumably on driving performance, are dose-related Centola et al. 2018) . The mean dose administrated in our study was 3333 mg (45-50 mg/kg). In human studies with lower GHB doses, 1-2 g did not significantly impair psychomotor skills related to driving (Mattila et al. 1978) . GHB at 12.5 and 25 mg/kg had no effects on attention, vigilance, or psychomotor coordination (Ferrara et al. 1999) , at 0.32-3.2 g/ 70 kg (4.5-45.7 mg/kg) produced dose-related changes in subjective effects but no changes in psychomotor performance (Oliveto et al. 2010) , and at 20 mg/kg had no significant effects on visual working memory, reaction time, and verbal recall (Bosch et al. 2015) . In studies using higher GHB doses (Carter et al. 2006) , 8 g/70 kg (114 mg/kg) produced sedation in almost all participants, and in approximately one third painful stimuli were required to elicit a response. Similar to our study, maximal effects occurred 1 to 2 h after administration and did not last more than 3-4 h. In studies with recreational GHB users, sedative effects reached their maximum between 1.5 and 2 h after a dose of 40 or 60 mg/kg, and returned to baseline after about 3 h (Abanades et al. 2007 ). At 4.5 g/70 kg (64.3 mg/kg) dose in healthy volunteers, Xyrem® significantly impaired working memory performance and encoding of episodic memory, and tended to increase response times (Carter et al. 2009 ). GHB doses up to 10 g/70 kg (143 mg/kg) had similar effects to alcohol dosed up to 120 g/70 kg (1714 mg/kg) regarding sedative effects and performance impairment, but less severe memory impairing effects and a shorter time course (Johnson and Griffiths 2013) . Thus, despite different methodological approaches (Centola et al. 2018 ), a dose threshold seems to exist, with lower or moderate doses probably not leading to impairment of psychomotor and driving skills, while GHB doses similar to those used in our study (or higher) pose a potential risk.
In studies of cases of driving under the influence (DUI) of GHB, mean reported blood GHB concentrations were between 87 and 100 mg/L (range 16-350 mg/L) (Jones et al. 2007; Pan et al. 2001; Couper and Logan 2001; Couper and Logan 2004; Burch et al. 2013 ) and reported clinical findings included slurred speech, stagger, drowsiness, stopping in the middle of the road, and sleeping (Jones et al. 2007; Pan et al. 2001; Burch et al. 2013) . Although the 1-h concentrations in our study (median 83.1 mg/L) are comparable to the reported DUI values, in the DUI cases, the blood samples were typically drawn one or more hours after the arrest. The half-life of GHB is reported to be between 20 and 50 min (Schep et al. 2012; Liechti et al. 2016; Brenneisen et al. 2004; Schröck et al. 2014; Thai et al. 2006; Thai et al. 2007 ), so it is assumed that the GHB concentrations were higher at the time of the arrest (Busardò and Jones 2015) .
Limitations of our study include the fact that we studied only one dose of GHB, which also had to be adjusted during the study for four participants due to safety reasons. Despite this, the doses we used are between the recommended starting and maximum doses used in treating narcolepsy, so we can provide a basis for advising narcolepsy patients regarding GHB residual effects and driving restrictions. However, while sodium oxybate is used before going to sleep in narcolepsy patients, for the treatment of alcohol craving (non-FDA use) it is dosed at 50 mg/kg/day, in three divided doses during the day at intervals of at least 4 h (Keating 2014; Drasbek et al. 2006 ). This dosing regimen would probably result in lower individual doses and therefore probably in less driving performance impairment. Furthermore, we did not include regular GHB users, who might have shown less driving impairment due to tolerance, as seen with repeated administration in mice and rats (Bania et al. 2003; Itzhak and Ali 2002) . Another potential limitation of the study is the large amount of practice (practice effect) required to master the use of the simulator (Lenne 2003) . We minimized the confounding of a practice effect by extensive training on the simulator-two 4-h sessions, then an 8-h session that mimicked the study day, and one final practice session 1 h prior to the pre-dosing baseline session. Also, the order of testing GHB and placebo was balanced. Moreover, no mathematical correction for multiple comparisons was performed for the pre-designed comparisons in our study. Although this might increase the risk for type I errors (e.g., in case of mean speed deviation 6 h post dosing), avoiding type II errors is of great importance when investigating life-threatening outcomes. Furthermore, a large effect size (r > 0.5) was found for most of the significant findings (including the life-threatening adverse outcome BNo. of collisions^) and those results remain significant even after lowering the alpha level to p < 0.01. This is the first controlled clinical study of the effect of GHB on driving and could be used, similar to alcohol driving simulation studies, to optimize patient safety and regulations regarding threshold for DUI offenses. As highlighted also in a recent review about the effects of GHB on driving performance (Centola et al. 2018) , there are currently no other experimental studies based on real-driving or driving simulators and the only knowledge in this field is derived from laboratory tests, which are not always reliable for the evaluation of the effects on driving. Therefore, our study offers an important basis in order to be able to advise patients about possible significant risks, especially in the light of further possible GHB indications currently under investigation (e.g., fibromyalgia (Russell et al. 2009 ), myoclonus, essential tremor (Frucht et al. 2005) , binge-eating disorder (McElroy et al. 2011) , and spasmodic dysphonia (Rumbach et al. 2017) ).
In conclusion, we found that at GHB doses used to treat narcolepsy, driving performance, as measured by a driving simulator, was subjectively (questionnaire) and objectively (collisions, etc.) significantly impaired 1 h after dosing with GHB, but the impairment resolved by 3 to 6 h post dosing. Data presented here do not indicate that any daytime driving restriction should be placed upon driving licenses of people with narcolepsy who take GHB at nighttime and do not drive until the morning. As regards daytime dosing of GHB for other medical conditions, no recommendations can be made about the safety of its use, similar to use in non-therapeutic setting in which higher doses might be used several times per day and often in combination with other substances. The 1-h GHB concentrations that we found in our study are in the range reported in the literature for GHB-DUIs. However, the DUI samples were collected one or more hours after the arrest. Although more study is needed before general driving recommendations can be made regarding GHB use, at this time, our data would indicate driving within 3-4 h of use may be hazardous and is not recommended.
